Navigation Links
Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
Date:1/27/2010

g proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic™ development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

SOURCE Sangamo BioSciences, Inc.

RELATED LINKS
http://www.sangamo.com

'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment of ... Executive Officer.  Mark was promoted from his current role of ... four facilities in Massachusetts , ... Medical in 2012 with 20+ years of broad-based operations, sales, ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty ... and Chief Executive Officer, will provide an overview and update ... Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012 at ... in Las Vegas, Nevada. The presentation will be webcast live ...
...  Express Scripts, Inc. (Nasdaq: ESRX ) announced that ... 2012 Healthcare Conference on May 16, 2012 at 1:00 p.m. ... in Las Vegas, Nevada. This presentation will also ... the investor relations section of Express Scripts, web site at ...
Cached Medicine Technology:Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference 2
(Date:4/17/2014)... that India,s shocking rates of suicide are highest in ... to tiny smallholdings less than one hectare ... and coffee, that are highly susceptible to global price ... case studies that point to a crisis in key ... the nation,s economy during the 90s. Researchers say that ...
(Date:4/17/2014)... after they suffer a cardiac arrest outside of a ... according to new research conducted at St. Michael,s Hospital. ... cardiac arrest get adrenaline, which has been the drug ... Steve Lin, an emergency physician and trauma team leader ... long-term survival rates of patients who suffer a cardiac ...
(Date:4/17/2014)... treatment that lost its status as the leading weapon ... lease of life, with new research indicating it simply ... revive the use of the cheap anti-malarial drug chloroquine ... the lives of more than half a million people ... causes malaria has developed resistance to chloroquine, but research ...
(Date:4/16/2014)... marvel of the embryo. It begins as a glob of ... to become the cells of our lungs, muscles, nerves and ... in a feat of reverse tissue engineering, Stanford University researchers ... embryonic cells to proliferate and transform into all of the ...
(Date:4/16/2014)... HAMPTON, NJ (April 16, 2014): Celldex Therapeutics, Inc. ... Phase 1 study of CDX-1401 in solid tumors, including ... Translational Medicine (Vol 6 Issue 232). The data ... of clinical benefit in patients with very advanced cancers ...
Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... developed a blood test for early detection of ovarian cancer//. ... as it is very difficult to diagnose during its early ... of the ovaries, like the surface epithelial cells, germ cells, ... women is ranked 4th in terms of causing deaths due ...
... said that it is better// to go for surgery while ... see if the disease progresses. ,Surgery for treating prostate ... researchers had conducted he study to see if prostatectomy done ... than watching and waiting the cancer in the prostate gland ...
... reduce the risk of kidney failure in men.// ,The ... of alcohol weekly (about a glass a day) and compared ... men who drank less than a glass a day of ... function of these men through a period of 14 years. ...
... study published in the May issue of the journal Neurology ... may be competent to take decisions about their treatments, but ... not remain competent to do so. ,The study also ... and its growth in the mare more likely to take ...
... cholesterol in the blood can increase the risk of having ... recent issue of British Journal of Cancer says that the ... testicular cancer by almost as much as 4.5 % than ... Swedish researchers from Karolinska University Hospital had looked into the ...
... pregnancy not only decides the health// of the fetus, it ... ,In a study to understand fetal development and mother’s ... on the genetic code of the fetus that may affect ... provided evidence that adverse effects of intrauterine environments can be ...
Cached Medicine News:
... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
... Design for Unparalleled Comfort Pick one of ... balance. Notice the trigger and ejector positionsright where ... our pipettors are ergonomically designed to help avoid ... pipetting. Productivity In The Palm Of Your ...
... Ergonomic Design for Unparalleled Comfort Pick one ... the balance. Notice the trigger and ejector positionsright ... because our pipettors are ergonomically designed to help ... of pipetting. Productivity In The Palm Of ...
... The Finnpipette BioControl multichannel has ... the single channel model. The ... seven multichannel and five single ... pipettes have a recharge and ...
Medicine Products: